276
Participants
Start Date
December 5, 2016
Primary Completion Date
July 5, 2018
Study Completion Date
July 5, 2018
Dupilumab SAR231893 (REGN668)
"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
Placebo
"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
Mometasone furoate 50 micrograms
"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
Investigational Site Number 3480006, Budapest
Investigational Site Number 3480007, Budapest
Investigational Site Number 3480004, Budapest
Investigational Site Number 3480003, Budapest
Investigational Site Number 1000002, Sofia
Investigational Site Number 1000001, Sofia
Investigational Site Number 1000003, Plovdiv
Investigational Site Number 3480005, Debrecen
Investigational Site Number 3480001, Szeged
Investigational Site Number 3480002, Pécs
Investigational Site Number 2030004, Prague
Investigational Site Number 2760001, Berlin
Investigational Site Number 3800005, Rozzano
Investigational Site Number 3800004, Milan
Investigational Site Number 3800006, Milan
Investigational Site Number 3800003, Varese
Investigational Site Number 8400015, Norfolk
Investigational Site Number 8400008, Winston-Salem
Investigational Site Number 8400018, Charleston
Investigational Site Number 2500002, Toulouse
Investigational Site Number 8400013, Tampa
Investigational Site Number 2500001, Montpellier
Investigational Site Number 8040001, Poltava
Investigational Site Number 3800007, Bologna
Investigational Site Number 2500006, Nantes
Investigational Site Number 8040008, Ternopil
Investigational Site Number 2760002, Münster
Investigational Site Number 2030001, Hradec Králové
Investigational Site Number 8400022, West Des Moines
Investigational Site Number 2030002, Pardubice
Investigational Site Number 8400010, Milwaukee
Investigational Site Number 2500004, Vandœuvre-lès-Nancy
Investigational Site Number 8400005, Rochester
Investigational Site Number 3800001, Pisa
Investigational Site Number 2500007, Lille
Investigational Site Number 8040004, Kharkiv
Investigational Site Number 8400021, St Louis
Investigational Site Number 2500003, Lyon
Investigational Site Number 8400019, Tulsa
Investigational Site Number 8400001, Dallas
Investigational Site Number 8040002, Ivano-Frankivsk
Investigational Site Number 8400016, Centennial
Investigational Site Number 2760003, München
Investigational Site Number 2500005, La Roche-sur-Yon
Investigational Site Number 8400009, Long Beach
Investigational Site Number 8400014, San Diego
Investigational Site Number 8400004, Orange
Investigational Site Number 3800002, Catania
Investigational Site Number 8400002, Stockton
Investigational Site Number 8400020, Medford
Investigational Site Number 6430004, Moscow
Investigational Site Number 6430003, Moscow
Investigational Site Number 6430006, Yaroslavl
Investigational Site Number 6430002, Saint Petersburg
Investigational Site Number 6430001, Saint Petersburg
Investigational Site Number 6430007, Saint Petersburg
Investigational Site Number 6420008, Craiova
Investigational Site Number 6420009, Cluj-Napoca
Investigational Site Number 6420007, Brasov
Investigational Site Number 6420013, Brasov
Investigational Site Number 6420010, Târgu Mureş
Investigational Site Number 8400007, Boston
Investigational Site Number 8400003, Nashville
Investigational Site Number 5280001, Amsterdam
Investigational Site Number 6160002, Katowice
Investigational Site Number 6160001, Lodz
Investigational Site Number 6160003, Warsaw
Investigational Site Number 6420003, Bucharest
Investigational Site Number 8040005, Kyiv
Investigational Site Number 8040006, Kyiv
Investigational Site Number 8260001, Bradford
Investigational Site Number 8260002, Dundee
Investigational Site Number 8260007, Great Yarmouth
Investigational Site Number 8260006, London
Investigational Site Number 8260004, Stockport
Investigational Site Number 8260005, Wigan
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY